Regeneron Q1 revenue up 7% to $3.16B; GAAP EPS $7.17; non-GAAP $10.09

REGENERON PHARMACEUTICALS, INC.

2023-Q1 EPS reported $7.17 revenue$3,162,100,000

Q1 total revenue $3.162B (+7% YoY); GAAP net income $818M (-16%); non-GAAP net income $1.168B (-11%).
EYLEA U.S. net sales $1.43B (-6% YoY); Dupixent global net sales $2.49B (+37%, recorded by Sanofi).
Aflibercept 8 mg BLA accepted for FDA priority review; target action date June 27, 2023 for wet AMD and DME.
Dupixent Phase 3 COPD trial met endpoints: 30% reduction in exacerbations; first biologic to show benefit in COPD.
Full-year 2023 guidance: GAAP R&D raised to $4.225-4.465B; GAAP SG&A raised to $2.49-2.68B; gross margin lowered to 87-89%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REGENERON PHARMACEUTICALS, INC. reported financial results for the first quarter of 2023.

Period: the first quarter of 2023
Result: reported results

Exact text from the filing

On May 4, 2023, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

REGENERON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001804220-23-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.